{
  "image_filename": "table_p3_det_2_009.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p3_det_2_009.png",
  "image_type": "Table",
  "page_number": 3,
  "block_id": "det_2_009",
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "supports_claim": false,
  "explanation": "A table comparing solicited adverse events (e.g., fever, fatigue, muscle pain, headache) by severity (mild, moderate, severe) in participants receiving FluBlok (N=2344) versus placebo (N=2304). The table lists counts and percentages for each symptom and severity category. does not support the claim because the table only presents post\u2010vaccination solicited adverse event data and does not address vaccine production methods, mutations during manufacturing, or their impact on effectiveness. Note: The image quality is sufficient to see that the content is focused on adverse event rates; it does not include information about vaccine production or mutations.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table comparing solicited adverse events (e.g., fever, fatigue, muscle pain, headache) by severity (mild, moderate, severe) in participants receiving FluBlok (N=2344) versus placebo (N=2304). The table lists counts and percentages for each symptom and severity category.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only presents post\u2010vaccination solicited adverse event data and does not address vaccine production methods, mutations during manufacturing, or their impact on effectiveness.",
    "confidence_notes": "The image quality is sufficient to see that the content is focused on adverse event rates; it does not include information about vaccine production or mutations."
  }
}